BioSpace News Archive

EyePoint Pharmaceuticals, Inc. today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will present at the H.C. Wainwright Ophthalmology Virtual Conference being held on August 17, 2021.

Rezolute, Inc. today announced that the Company has initiated dosing in a Phase 1b multiple-ascending dose study of RZ402, Rezolute’s investigational oral plasma kallikrein inhibitor (PKI) for the treatment of diabetic macular edema (DME).

Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced the publication of an exploratory analysis evaluating the safety of OLINVYK injection and IV morphine, using data from the OLINVYK Phase 3 program.

Positive Interim Assessment Outcome for EscharEx U.S. Phase II Clinical Study No Changes to Study Sample Size – No Safety Concerns Identified.

Finch Therapeutics Group, Inc. today announced that Takeda Pharmaceutical Company Limited (“Takeda”) has elected to accelerate the transition of development responsibility for the FIN-524 ulcerative colitis development program.

AzurRx BioPharma, Inc., a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal diseases, announced the completion of site initiation visits and the addition of five new clinical trial sites in Ukraine for the ongoing RESERVOIR Phase 2 clinical trial evaluating FW-1022 as a treatment for COVID-19-related gastrointestinal infections.

CASI Pharmaceuticals, Inc. today announced the Company will host a conference call reviewing the second quarter highlights at 8:00 a.m. ET on Thursday , August 12 th , 2021.

Apollomics Inc. today announced the successful dosing of the first patient in a Phase I clinical study of APL-102 in patients with advanced solid tumors.

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today reported business highlights and financial results for the second quarter ended June 30, 2021.

Decibel Therapeutics today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.